Dr. Melnick is being recognized for “significant research contributions to the treatment of acute myeloid leukemia through an improved understanding of epigenetics.”
Initiated in 2002, the award is given to fellows within the Weill Department of Medicine who have performed outstanding research. This year's finalists were presented at Medicine Grand Rounds on June 17.
Patients with the most common type of metastatic pancreatic cancer showed improved results when treated with a combination of an investigational drug, an immunotherapy drug, and chemotherapy.
In response to the COVID-19 pandemic, faculty from across the Weill Department of Medicine have been pursuing critical research.
In this role, he will establish an office of entrepreneurship while working closely with senior leadership and investigators at Weill Cornell Medicine, Cornell’s Ithaca campus, Cornell Tech, the Tri-Institutional community, and other partners.
Dr. Shore will represent the WDOM on compliance matters related to the department, and provide leadership in support of the inpatient service to ensure high quality patient care.
In this pivotal role, he will work closely with Weill Cornell Medicine and NewYork-Presbyterian Hospital leadership to promote and ensure exceptional patient care in the ambulatory setting.
Dr. Melnick and his team have developed an SIRT3-blocking compound that rapidly kills diffuse large B cell lymphoma cells in the culture dish and in mice.
This award is presented annually to members of the Weill Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research.
Dr. Silver received the award in recognition of his contributions to international integration of research in the field of leukemia.
